Rich Steffens
Long only, value, momentum, event-driven

Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer

This article covers stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.


The word alone makes you shiver.

Every year, there are approximately 230,000 women diagnosed with breast cancer in the United States. According to the National Cancer Institute, of these women, about 75% test positive for HER2 (IHC 1+, 2+ or 3+). Out of these, only 25% of all breast cancer patients, those with HER2 3+ disease, are eligible for Herceptin®, from Roche (OTCQX:RHBY) and Genentech, which had revenues of over $6 billion in 2012.

The remaining 50% of low HER 2 expressing patients, or those that...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details